Cardiff Oncology beats earnings and revenue estimates
ArchivedVerified|4 articles|2 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Cardiff Oncology reported earnings per share that beat estimates by $0.08 on February 25, 2026.
- •The company's revenue for the quarter surpassed analyst projections.
- •The earnings report was released ahead of market open on February 25, 2026.
What Could Happen If...
- ▸If Cardiff Oncology continues to report earnings above estimates investors may increase demand for the company's shares, potentially raising its stock price.
Key Actors
Organizations
Source Coverage
FINANCE
4 articles
More coverage on this story
- More on Cardiff Oncology
Signals
Single-block coverageLow source diversity
Related Events
▸Anterix earnings beat by $0.25, revenue topped estimatesArchived▸Sun quarterly profit beats Wall Street forecastsArchived▸GoodRx Holdings Reports Q4 Non-GAAP EPS $0.09, Revenue $195MArchived▸eXp World EPS and Revenue Beat Estimates Despite LossArchived▸Jackson Financial Non-GAAP EPS of $6.61 beats by $0.75, revenue of $1.99B beats by $70M
Primary Sources (4)
FINANCESeeking Alpha - Market NewsInternational Seaways Non-GAAP EPS of $2.45 beats by $0.49, revenue of $267.8M beats by $30MFINANCESeeking Alpha - Market NewsEarnings Snapshot: Teladoc Health guidance falls short; U.S. revenue down 3%, international up 19%FINANCEInvesting.com - NewsMiMedx earnings beat by $0.05, revenue topped estimatesFINANCE